Zoledronic acid and Psoriasis - a phase IV clinical study of FDA data

Summary:

Psoriasis is reported as a side effect among people who take Zoledronic acid (zoledronic acid), especially for people who are female, 50-59 old, also take Ezetimibe, and have Hypothyroidism.

The phase IV clinical study analyzes which people have Psoriasis when taking Zoledronic acid. It is created by eHealthMe based on reports of 28,440 people who have side effects when taking Zoledronic acid from the FDA, and is updated regularly.

What is Zoledronic acid?

Zoledronic acid has active ingredients of zoledronic acid. eHealthMe is studying from 28,485 Zoledronic acid users. Check the latest studies of Zoledronic acid.

What is Psoriasis?

Psoriasis (immune-mediated disease that affects the skin) is found to be associated with 1,478 drugs and 1,694 conditions by eHealthMe. Check the latest studies of Psoriasis.

On Aug, 02, 2026

28,440 people reported to have side effects when taking Zoledronic acid.
Among them, 11 people (0.04%) have Psoriasis.

Among these 11 people:

What is the gender of people who have Psoriasis when taking Zoledronic acid? *

female: 63.64 %
male: 36.36 %

What is the age of people who have Psoriasis when taking Zoledronic acid? *

What are other drugs people take besides Zoledronic acid? *

Sulfasalazine: 4 people, 36.36%
Cosentyx: 4 people, 36.36%
Metformin Hydrochloride: 4 people, 36.36%
Ezetimibe: 4 people, 36.36%
Pantoprazole: 2 people, 18.18%
Calcium: 2 people, 18.18%
Pomalyst: 2 people, 18.18%
Zyvox: 1 person, 9.09%
Hydrocortisone: 1 person, 9.09%
Hydrochlorothiazide: 1 person, 9.09%

What are other side effects people have besides Psoriasis? *

Arthritis (form of joint disorder that involves inflammation of one or more joints): 5 people, 45.45%
Stress And Anxiety: 5 people, 45.45%
Joint Pain: 5 people, 45.45%
Bone Pain: 4 people, 36.36%
Thyroid Diseases: 4 people, 36.36%
Hypersensitivity: 4 people, 36.36%
Hair Loss: 4 people, 36.36%
Decreased Immune Responsiveness: 4 people, 36.36%
Feeling Abnormal: 4 people, 36.36%
Metabolic Disorder (an abnormal function and pattern of body fat. insulin resistance refers to the diminished ability of cells to respond to the action of insulin in promoting the transport of the sugar glucose, from blood into muscles and other tissues): 4 people, 36.36%

What are the existing conditions these people have? *

Joint Pain: 4 people, 36.36%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 4 people, 36.36%
Dyslipidaemia (abnormal amount of lipids): 4 people, 36.36%
Glucose Tolerance Impaired (blood glucose is raised beyond normal levels, but not high enough to warrant a diabetes diagnosis): 4 people, 36.36%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 36.36%
Multiple Myeloma (cancer of the plasma cells): 2 people, 18.18%
High Blood Pressure: 1 person, 9.09%
Bone Pain: 1 person, 9.09%
Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi): 1 person, 9.09%
Constipation: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Zoledronic acid and have Psoriasis?

- Check whether Psoriasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zoledronic acid:

Zoledronic acid (28,485 reports)

Psoriasis treatments and more:

Psoriasis (508,164 reports)

Browse all side effects of Zoledronic acid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Psoriasis:

Psoriasis (1,478 drugs)

Browse all the conditions that are associated with Psoriasis:

Psoriasis (1,694 conditions)

Related publications that referenced our studies

Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on zoledronic acid (the active ingredients of Zoledronic acid) and Zoledronic acid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.